Two ACEs in the pack

A genomics-based approach has uncovered the first human homologue of ACE (angiotensin-converting enzyme).

September 28, 2000

A study published in the online version of Circulation Research describes the discovery of ACE-related carboxypeptidase (ACE2) — the first human homologue of the protein ACE (angiotensin-converting enzyme). ACE2 was identified by scientists at Millennium Pharmaceuticals in Massachusetts, and is significant because it is restricted to the heart, kidneys and testes, potentially offering a specific target for drug treatment of hypertension and congestive heart failure.

ACE2 was identified during Millennium's ongoing search for novel genes related to heart failure, which involves sequencing thousands of tissue biopsies from its 'human heart failure ventricle' cDNA library. ACE and ACE2 have only 42% similarity; ACE2 is not inhibited by lisinopril or captopril, and produces an angiotensin peptide whose function is currently unknown. "The organ and cell-specific expression of ACE2 and its unique cleavage of key vasoactive peptides suggest an essential role for ACE2 in the local renin–angiotensin system of the heart and kidney," the researchers conclude. Millennium is now working with Eli Lilley to pursue the development of drugs targeted at ACE2 for the treatment of heart failure.

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham